14th May 2026 12:55
14 May 2026
("Proteome Sciences" or the "Company")
Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.
For information, the proxy votes received in relation to the resolutions were as follows:
RESOLUTION MATTER | VOTES FOR | VOTES AGAINST | VOTES DISCRETIONARY | VOTES WITHHELD | VOTES TOTAL |
1. To receive the report of the Directors and the audited Financial Statements of the Company for the year ended 31 December 2025. | 147,914,675 | 2,800,402 | 539 | 71,282 |
150,786,898 |
2. To receive and approve the Remuneration Report, excluding the remuneration policy. | 146,482,388 | 4,232,689 | 539 | 71,282 | 150,786,898 |
3. To re-appoint Christopher Pearce as a Director of the Company. | 147,740,986 | 2,890,589 | 0 | 155,323 | 150,786,898 |
4. To re-appoint Richard Dennis as a Director of the Company. | 147,704,238 | 2,947,337 | 0 | 135,323 | 150,786,898 |
5. To re-appoint Ian Pike as a Director of the Company. | 147,724,238 | 2,927,337 | 0 | 135,323 | 150,786,898 |
6. To re-appoint Ursula Ney as a Director of the Company. | 147,741,085 | 2,910,490 | 0 | 135,323 | 150,786,898 |
7. To re-appoint Martin Diggle as a Director of the Company. | 147,564,238 | 3,067,337 | 0 | 155,323 | 150,786,898 |
8. To re-appoint Cooper Parry Group Limited as auditors of the Company and to authorise the Directors to determine the remuneration of the auditors. | 147,796,267 | 2,890,439 | 0 | 100,192 | 150,786,898 |
9. To authorise the Directors to exercise all or any of the powers of the Company to allot equity securities up to an aggregate nominal amount of £1,168,966.13. | 147,727,873 | 2,978,396 | 0 | 80,629 | 150,786,898 |
10. To empower the Directors to dis-apply statutory pre-emption rights up to a maximum aggregate nominal amount of £701,449.82. | 146,526,989 | 4,179,957 | 0 | 79,952 | 150,786,898 |
Proteome Sciences plc | ||||
Christopher Pearce, Executive Chairman | Tel: +44 (0) 20 7043 2116 |
| ||
Dr. Ian Pike, Chief Scientific Officer |
| |||
Richard Dennis, Chief Commercial Officer |
| |||
| ||||
SP Angel Corporate Finance LLP (Nominated Adviser & Broker) |
| |||
David Hignell/Richard Morrison/Josh Ray (Corporate Finance) Vadim Alexandre (Corporate Broking)
| Tel: +44 (0) 20 3470 0470 |
| ||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the selectivity that drugs have to binding one or more proteins in the sample proteome. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
Further information on the Company can be found on its website at: https://www.proteomics.com/
The Company's LEI is 213800Q62ICXANKU2986.
This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.
Related Shares:
Proteome